Trial Profile
Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2020
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Lambert-Eaton myasthenic syndrome
- Focus Therapeutic Use
- 04 Oct 2017 New trial record